Hovione and Firstgene Announce Strategic Collaboration
Exclusive licensing and R&D collaboration between Hovione and Firstgene.
Cell & Gene Therapy (CGT)
06.01.2025 • News
GemmaBio Secures $34 Million in Funding
Gemma Biotherapeutics (GemmaBio), a new therapeutics company founded by gene therapy pioneer Jim Wilson, recently announced the completion of a $34 million seed funding round to accelerate its groundbreaking gene therapy initiatives.
28.11.2024 • News
Roche to Buy Poseida Therapeutics for $1.5 Billion
Roche has entered into a definitive merger agreement to acquire Poseida Therapeutics, a US clinical-stage biopharmaceutical company developing donor-derived CAR-T cell therapies, in a deal valued at approximately $1.5 billion.
22.11.2024 • News
Novartis Acquires Kate Therapeutics for $1.1 Billion
Swiss pharmaceutical giant Novartis has acquired Kate Therapeutics for $1.1 billion. The San Diego, US-headquartered preclinical stage biotechnology company develops adeno-associated virus (AAV)-based gene therapies to treat inherited neuromuscular diseases.
24.09.2024 • News
Lonza and Vertex Sign a Commercial Supply Agreement for Casgevy
Lonza and Vertex Pharmaceuticals recently announced a commercial supply agreement for casgevy (exagamglogene autotemcel).
Minicircle DNA
The minicircle has emerged as a Next Generation Gene Vector and as a promising tool in the field of gene delivery and therapeutic applications. This overview aims to cover the characteristics, production methods, and potential applications of minicircle DNA.
09.09.2024 • News
Medera to Go Public through Merger with KVAC
Keen Vision Acquisition Corp. (KVAC) and Medera, a clinical-stage biotechnology company, have entered into a merger agreement. Upon closing of the merger, which is expected to occur in the fourth quarter of 2024, the combined company will operate under the name Medera.
04.06.2024 • News
Ori Biotech Reveals Automated Platform for Cell & Gene Therapy Production
Ori Biotech a cell and gene therapy (CGT) manufacturing technology producer, recently announced the commercial launch of IRO, a next-generation platform.
Navigating the Logistics Impact
Cell and gene therapies (CGTs) present a revolutionary approach to the pharmaceutical industry. However, several complexities do arise on a logistical spectrum that diverge from those of traditional pharmaceuticals.
